METADATE CD CII
Generic Name and Formulations:
Methylphenidate HCl 10mg, 20mg, 30mg, 40mg, 50mg, 60mg; ext-rel caps (contains immediate-release + ext-rel beads); contains sucrose.
Indications for METADATE CD:
Attention deficit hyperactivity disorder.
Adults and Children:
Take before breakfast. Swallow whole or sprinkle contents onto applesauce (swallow immediately); do not crush, chew, or divide beads. <6yrs: not established. ≥6yrs: initially 20mg once daily, may increase weekly by 10–20mg/day; max 60mg once daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Surgery.
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH. Risk of serotonin syndrome with serotonergic drugs.
Headache, anorexia, abdominal pain, insomnia, dizziness, nervousness; priapism, hypertension, tachycardia, visual disturbances.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy